PRESCRIBING · PART D · 2024
Total Rx claims
1,268
Beneficiaries
—
Total drug cost
$10.8M
Distinct drugs
19
Brand share
55.3%
Top prescribed drugs
Ruxolitinib Phosphate376 claims
Hydroxyurea356 claims
Momelotinib Dihydrochloride71 claims
Imatinib Mesylate71 claims
Bosutinib65 claims
QUALITY · MIPS · 2024
No data available for this provider in 2024.
CROSS-REFERENCE